In vivo, an intraovarian cancer cell injection model demonstrated that targeting stromal MFAP5 using siRNA delivered by nanoparticles significantly reduced tumor growth and metastasis [90], suggesting that targeting the CAF-derived secretory factor is a new treatment approach for ovarian cancer. This evidence concerns the gene MFAP5 and ovarian cancer.